Seer (NASDAQ:SEER – Get Free Report) and Nautilus Biotechnology (NASDAQ:NAUT – Get Free Report) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their earnings, dividends, institutional ownership, risk, profitability, analyst recommendations and valuation.
Earnings and Valuation
This table compares Seer and Nautilus Biotechnology’s gross revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Seer||$15.49 million||6.77||-$92.97 million||($1.49)||-1.10|
|Nautilus Biotechnology||N/A||N/A||-$57.92 million||($0.47)||-5.45|
Nautilus Biotechnology has lower revenue, but higher earnings than Seer. Nautilus Biotechnology is trading at a lower price-to-earnings ratio than Seer, indicating that it is currently the more affordable of the two stocks.
|Net Margins||Return on Equity||Return on Assets|
This is a summary of current recommendations and price targets for Seer and Nautilus Biotechnology, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Seer currently has a consensus price target of $8.25, indicating a potential upside of 403.05%. Nautilus Biotechnology has a consensus price target of $6.00, indicating a potential upside of 134.38%. Given Seer’s higher possible upside, research analysts clearly believe Seer is more favorable than Nautilus Biotechnology.
Insider & Institutional Ownership
63.9% of Seer shares are owned by institutional investors. Comparatively, 35.9% of Nautilus Biotechnology shares are owned by institutional investors. 15.0% of Seer shares are owned by insiders. Comparatively, 42.5% of Nautilus Biotechnology shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Risk & Volatility
Seer has a beta of 1.55, suggesting that its share price is 55% more volatile than the S&P 500. Comparatively, Nautilus Biotechnology has a beta of 1.13, suggesting that its share price is 13% more volatile than the S&P 500.
Nautilus Biotechnology beats Seer on 7 of the 12 factors compared between the two stocks.
Seer, Inc., a life sciences company, engages in developing and commercializing products to decode the secrets of the proteome. It develops Proteograph Product Suite, an integrated solution that comprises consumables, an automation instrumentation, and software that allows researchers to conduct proteomic studies in therapeutic and diagnostic research, and clinical trials. The company intends to sell its products for research purposes, which cover academic institutions, life sciences, and research laboratories, as well as biopharmaceutical and biotechnology companies for non-diagnostic and non-clinical purposes. Seer, Inc. has a collaboration agreement with Oregon Health & Science University; The Broad Institute of MIT and Harvard; Discovery Life Sciences, LLC. and the Salk Institute for Biological Studies. The company was formerly known as Seer Biosciences, Inc. and changed its name to Seer, Inc. in July 2018. Seer, Inc. was incorporated in 2017 and is headquartered in Redwood City, California.
About Nautilus Biotechnology
Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. It develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprised of instruments, consumables, and software analysis. The company was incorporated in 2016 and is headquartered in Seattle, Washington.
Receive News & Ratings for Seer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Seer and related companies with MarketBeat.com's FREE daily email newsletter.